1401074-29-0

Upstream product

• 64145-51-3 (S)-3-phenylcyclopentanone 
• 1401074-28-9 (S)-3-(4-bromophenyl)cyclopentanone oxime 
• 160678-59-1 (S)-3-(4-bromophenyl)cyclopentanone 

Downstream Products

• 1401074-27-8 1-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]-3-[(1R,3S)-3-phenylcyclopentyl]urea 
• 1401074-35-8 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-phenylcyclopentyl]urea 
• 1401074-36-9 1-(1H-indazol-4-yl)-3-[(1R,3S)-3-phenylcyclopentyl]urea 
• 1401074-42-7 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1S,3S)-3-phenylcyclopentyl]urea 
• 1401077-66-4 1-(1-chloroisoquinolin-5-yl)-3-[(1R,3S)-3-phenylcyclopentyl]urea 

Relevant academic research and scientific papers

COMPLEMENT PATHWAY MODULATORS AND USES THEREOF

The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

TRPV1 Antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.